Xenon MRI Pulm Hypertension
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18-75
SponsorBastiaan Driehuys
About this trial
The overall objective outlined in this study is to determine how pulmonary vascular remodeling in PAH at a cellular and pathological level is associated with changes in gas exchange physiology and hemodynamics (monitored with 129Xe MRI/MRS) and how these signals change with disease progression or treatment.
Eligibility criteria
Qualifiers
Outpatients of either gender, Age 18-75
Awaiting a lung transplant
Diagnosis of precapillary PH (right heart catheterization demonstrating hemodynamic criteria of a mean pulmonary artery pressure (mPAP) ≥ 25 mmHg, pulmonary vascular resistance ≥ 3 WU, pulmonary capillary wedge pressure ≤ 15 mmHg) in the setting of Group 1 (PAH), 3 (PH due to chronic lung disease, 4 (PH due to pulmonary artery obstructions), or 5 (PH due to miscellaneous causes)
Willing and giving informed consent and adhere to visit/protocol schedules (consent must be given before any study procedures are performed).
Disqualifiers
Moderate to severe heart disease (LVEF <45%, Severe LV hypertrophy, Moderate to severe valvular disease)
PH due to schistosomiasis
Active cancer
Sickle cell anemia
Trial design
Treatments tested in this trial
- 129Xe Hyperpolarized
Treatment groups
20 Participants
are divided into 2 treatment groupsSponsors and collaborators
Bastiaan Driehuys
Lead sponsor
Duke University
Sponsor institution
Source ClinicalTrials.gov